Navigation Links
University of Colorado Cancer Center earns major grant to develop new bladder cancer drugs
Date:8/15/2012

Bladder cancer kills by metastasizing usually to the lungs. A major grant from the National Cancer Institute will help the University of Colorado Cancer Center develop new drugs aimed at stopping bladder cancer's spread, which will kill an estimated 15,000 people in the United States this year.

"Strong preliminary work shows specific proteins that bladder cancer cells need in order to leave the bladder and attach to lung tissue. And additional work points to a number of drug candidates that block the activity of these proteins. The current project aims to select the best drug, use medicinal chemistry to boost its effectiveness, and move the optimized drug toward a human clinical trial," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center, who will co-lead the project with David Ross, PhD, chair of the Department of Pharmaceutical Sciences at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado.

The work is especially important in light of two current conditions: first, the extended absence of new drugs targeting bladder cancer, with the most recent advance being the addition of the drug gemcitabine, which earned FDA approval in 1997; and second, the recent explosion of technologies that allow the development of drugs that target a cancer's specific genetic abnormalities.

"We've seen a paradigm shift toward targeted therapies drugs that unlike the traditional chemotherapies selectively kill cancer cells while leaving healthy tissue unharmed. We hope to apply this paradigm to metastatic bladder cancer," says Colin Dinney, MD, co-principal investigator and chair of the Department of Urology at project partner MD Anderson.

"This project will target metastatic colonization in bladder cancer by targeting the proteins that drive these processes," says David McConkey, PhD, co-principal investigator at MD Anderson.

"We also hope to define the biomarkers of patients likely to respond to the drugs," Theodorescu says. Defining the population most likely to benefit from the new drugs would allow the group to select these patients for Phase I clinical trials the project's intended endpoint.

"We are all hopeful that three years from now, we'll have a drug in clinical trials that prevents or delays the development of metastatic disease high-risk patients following treatment of the primary tumor," Theodorescu says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Hospital of the University of Pennsylvania selected to lead US nurse-training initiative
2. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
3. Boston University researchers expand synthetic biologys toolkit
4. Canadians super-sizing Canadas Food Guide servings: York University study
5. Tel Aviv University researcher says plants can see, smell, feel, and taste
6. Tel Aviv University research links childhood obesity to cancer risk
7. Marshall University scientist awarded NIH grant for lung cancer research
8. University of Texas Medical Branch to study hospital readmission
9. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
10. Tannins in sorghum and benefits focus of university, USDA study
11. ASHA grant funds cutting-edge AIDS research at Tel Aviv University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ... pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, ... , Dr. Olson says the decision to support the pageant in an official ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its site, ... matching users with high quality water pipes within an ideal price range. The site ... was founded by two brothers, Nick and Mike Hunter, who use medical cannabis to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
(Date:6/23/2016)... WASHINGTON , June 23, 2016  The ... Pharmaceuticals has joined the health policy research organization ... Steven Romano , MD, senior vice president and ... his company,s representative on the NPC Board of ... are pleased that Mallinckrodt has joined us in ...
Breaking Medicine Technology: